Cancer-cell-specific cytostatic agent
AssigneeGenecare Research Institute Co., Ltd.
InventorsMotoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
Life of this patent
Estimating the term…
Abstract
The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.
Claims12
A double-stranded RNA that can suppress the expression of an RecQ1 gene by an RNAi effect, wherein the RNA comprises a structure in which an RNA comprising the nucleotide sequence of any one of SEQ ID NOs:
- 1 to 32 or SEQ ID NOs:
- 40 to 43 and an RNA comprising a sequence complementary to said RNA are hybridized.
A DNA vector that can express an RNA comprising the nucleotide sequence of any one of SEQ ID NOs:
- 1 to 32 or SEQ ID NOs:
- 40 to 43.
A method for suppressing cancer cell-specific cell proliferation, which comprises administering a double-stranded RNA comprising the nucleotide sequence of any one of SEQ ID NOs:
- 1 to 32 or SEQ ID NOs:
- 40 to 43 and a sequence complementary thereto or a DNA vector encoding the RNA to a subject in need thereof.
Dependencies are inferred from the claim text.